Omron Healthcare has partnered with physIQ to integrate Omron’s wearable blood pressure monitor, HeartGuide, into physIQ’s pinpointIQ® platform to monitor at-risk patients in an outpatient setting. The partnership is aimed at generating actionable clinical information for at-risk patients in an outpatient environment by leveraging the complementary technologies of each company. Omron is the global leader in personal heart health and wellness technology and physIQ is a pioneer in FDA-cleared Artificial Intelligence physiology analytics.
Omron recently announced the retail availability of its HeartGuide blood pressure monitoring smartwatch at the CES 2019, where it was awarded the Engadget “Best of CES” award for best wearable. The HeartGuide smartwatch uses oscillometric technology to measure medically-accurate blood pressure readings and monitors activity and sleep. PhysIQ’s pinpointIQ solution is an enterprise-ready, device-agnostic platform designed to capture continuous multivariate physiological data from wearable sensors, apply FDA-cleared Artificial Intelligence-based analytics, and provide actionable clinical information to a patient’s care team, said a press release.
“At Omron, our mission is Going for Zero, the elimination of heart attack and stroke,” said Ranndy Kellogg, president and CEO of Omron Healthcare. “HeartGuide is a significant step forward in Going for Zero and the addition of advanced analytics builds on that advancement to give even higher risk patients greater power in managing their condition and reducing their risk of an event. We are committed to working with physIQ to leverage their industry-leading platform and human physiology analytics to provide better care for patients.”
The collaborative work will start with a major Chicago-area integrated health system and focus on supporting post-discharge patients who have been hospitalized for either heart failure or heart attack. Patients will wear HeartGuide, which will transmit data through the physIQ mobile app to the pinpointIQ cloud-based platform. Clinicians will access patient data and analytics through the pinpointIQ user interface such that they can proactively manage their at-risk patients.
Gary Conkright, CEO of physIQ said they long believed that high-frequency real world blood pressure could reveal patient physiology in an unprecedented manner. “By integrating HeartGuide into our pinpointIQ platform, we are confident that we have an end-to-end solution that will address a massive unmet need in the market and bring enormous value to patients and their clinicians. This is the beginning of a relationship that we believe will truly transform how patients are cared for at home,” he said.